Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: Still work in progress

Salvatore Fuschillo, Antonio Molino, Cristiana Stellato, Andrea Motta, Mauro Maniscalco

Research output: Contribution to journalReview articlepeer-review

Abstract

Disease phenotyping is a key step towards an increasingly personalized approach to chronic obstructive pulmonary disease (COPD), leading to a more precise assessment, treatment and definition of disease outcomes. The search for biomarkers able to guide the identification of COPD phenotypes are of great importance for both researchers and clinicians. However, while several biomarkers of inflammation [e.g., peripheral blood eosinophils and fractional expired nitric oxide] have been identified and applied in asthma, none has been successfully linked to discrete clinical parameters of COPD such as exacerbations, natural progression, and treatment response or mortality risk. Recently, several studies have shown that blood eosinophils are a potential biomarker for patient subset stratification in COPD therapy. Here we reviewed the value of blood eosinophils in predicting the response of COPD patients to treatment.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalEuropean Journal of Internal Medicine
Volume68
DOIs
Publication statusPublished - Oct 2019

Fingerprint Dive into the research topics of 'Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: Still work in progress'. Together they form a unique fingerprint.

Cite this